Bio News
GC Cell said its CD5-targeted CAR-NK cell therapy GCC2005 received approval from the Ministry of Food and Drug Safety for therapeutic use.
Seoul National University Hospital plans to administer GCC2005 to a patient with peripheral T-cell lymphoma whose treatment options are limited.
GC Cell plans to work with the Seoul National University Hospital research team to support the patient’s treatment and continue development of the therapy in a phase 1b clinical trial.
BIOBOOK TEAM
biobookmedia@biobook.co.krAspen Neuroscience and Bambusa Plan U.S. IPOs; Developers of Parkinson’s and Bispecific Antibody Therapies
St. Jude Identifies Cell Marker for High-Risk Neuroblastoma
University of Texas at Austin Develops Flexible Electrode for Recording Brain Waves for a Month Without Shaving Hair
Revolution Medicines Shares Fall 6.3% on Concerns About RASONK’s KRAS Subgroup
GSK Adopts Chai Discovery AI Model After Wet-Lab Validation
Teva Wins FDA Approval for Long-Acting Olanzapine Beltruzza for Schizophrenia
Peptone nears end of two-year Lilly technology evaluation…follow-on deal could be pivotal
HLB Pharmaceutical Completes 60.8 Billion Won Rights Offering, Bets on New Hyangnam Plant as Management Participation Grows
Song Young-sook sells 86 billion won stake; buyer is daughter’s one-person company — Is a second round of Hanmi control battle looming?
